The incidence and mortalities from cancers remain on the rise worldwide. Despite significant efforts to discover and develop novel anticancer agents, many cancers remain in the unmet need category. As such, efforts to discover and develop new and more effective and less toxic agents against cancer remain a top global priority. Our drug discovery approach is natural products based with a focus on plants. Tillandsia recurvata (L.) L. is one of the plants selected by our research team for further studies based on previous bioactivity findings on the anticancer activity of this plant.
The plant biomass was extracted using supercritical fluid extraction technology with CO2 as the mobile phase. Bioactivity guided isolation was achieved by use of chromatographic technics combined with anti-proliferative assays to determine the active fraction and subsequently the pure compound. Following in house screening, the identified molecule was submitted to the US National Cancer Institute for screening on the NCI60 cell line panel using standard protocols. Effect of HLBT-100 on apoptosis, caspase 3/7, cell cycle and DNA fragmentation were assessed using standard protocols. Antiangiogenic activity was carried out using the ex vivo rat aortic ring assay.
A flavonoid of the flavanone class was isolated from T. recurvata (L.) L. with potent anticancer activity. The molecule was code named as HLBT-100 (also referred to as HLBT-001). The compound inhibited brain cancer (U87 MG), breast cancer (MDA-MB231), leukemia (MV4-11), melanoma (A375), and neuroblastoma (IMR-32) with IC50 concentrations of 0.054, 0.030, 0.024, 0.003 and 0.05 µM, respectively. The molecule also exhibited broad anticancer activity in the NCI60 panel inhibiting especially hematological, colon, CNS, melanoma, ovarian, breast and prostate cancers. Twenty-three of the NCI60 cell lines were inhibited with GI50 values <0.100 µM. In terms of potential mechanisms of action, the molecule demonstrated effect on the cell cycle as evidenced by the accumulation of cells with <G1 DNA content, activation of caspase 3/7, DNA fragmentation and culminating in apoptotic cell death. HLBT-100 also demonstrated antiangiogenic potential by inhibiting capillary sprout and tube formation in a dose dependent manner in the ex vivo rat aortic ring.
This paper describes for the first time the anticancer activity of HLBT-100 isolated from T. recurvate (L.) L. The broad and selective anticancer activity of HLBT-100 as evidenced by its potent activity against IMR-32, CNS cancer cell line while not active against neuro-2a, a normal CNS cell line. The activity demonstrated by HLBT-100 in these studies makes the molecule a potential candidate for further development targeting especially those cancers that remain in the unmet need category such as glioblastoma multiforme and acute myeloid leukemia in addition to other cancers.
WHO Cancer Fact Sheet No. 297. http://www.who.int/mediacentre/factsheets/fs297/en/. Accessed 3 Sept 2016.
US National Cancer Institute Cancer Statistics. http://www.cancer.gov/about-cancer/understanding/statistics. Accessed 3 Sept 2016.
Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomark Prev. 2010;19(8):1893–907. CrossRef
Bernhoft A. A brief review. In: Bernhoft A, editor. Bioactive compounds in plants benefits and risks for man and animals. Oslo, Norway: The Norwegian Academy of Science and Letters; 2010. pp. 11–7.
Azmir J, Zaidul I, Rahman M, Sharif K, Mohamed A, Sahena F, Jahurul M, Ghafoor K, Norulaini N, Omar A. Techniques for extraction of bioactive compounds from plant materials: a review. J Food Eng. 2013;117(4):426–36. CrossRef
Bernal R, Valverde T, Hernandez-Rosas L. Habitat preference of the epiphyte Tillandsia recurvata (Bromeliaceae) in a semi-desert environment in Central Mexico. Botany. 2005;83(10):1238–47.
Cabrera GM, Seldes AM. Hydroperoxycycloartanes from Tillandsia recurvata. J Nat Prod. 1995;58(12):1920–4. CrossRef
Lowe H, Toyang N, Bryant J. In vitro and In vivo anti-cancer effects of Tillandsia recurvata (Ball Moss) from Jamaica. West Indian Med J. 2013;62(3):177–80. PubMed
Lowe H, Watson CT, Badal S, Ateh EN, Toyang NJ, Bryant J. Antiangiogenic properties of the Jamaican ball moss ( Tillandsia recurvata L.). Int Res J Biol Sci. 2012;1:73–6.
Lowe HI, Watson CT, Badal S, Toyang NJ, Bryant J. Cycloartane-3,24,25-triol inhibits MRCKα kinase and demonstrates promising anti prostate cancer activity in vitro. Cancer Cell Int. 2012;12(1):1. CrossRef
Lowe HI, Watson CT, Badal S, Toyang NJ, Bryant J. Kinase inhibition by the Jamaican ball moss, Tillandsia recurvata L. Anticancer Res. 2012;32(10):4419–22. PubMed
Beecher GR. Overview of dietary flavonoids: nomenclature, occurrence and intake. J Nutr. 2003;133(10):3248S–54S. PubMed
Iwashina T. The structure and distribution of the flavonoids in plants. J Plant Res. 2000;113(3):287–99. CrossRef
Maru G, Kumar G, Ghantasala S, Tajpara P. Polyphenol (s)-mediated in vivo cellular responses during carcinogenesis. Polyphenols in health and diseases. Amsterdam: Elsevier; 2014. p. 1141–79.
Tapas AR, Sakarkar D, Kakde R. Flavonoids as nutraceuticals: a review. Trop J Pharm Res. 2008;7(3):1089–99. CrossRef
Stapel J, Oppermann C, Richter D, Ruth W, Briese V. Polyphenol compounds with anti-carcinogenic qualities: effects of quercetin (flavonol), chrysin (flavon), kaempferol (flavanol), naringenin (flavanon) and hesperidin (flavanoid) on in vitro breast cancer. J Med Plants Res. 2013;7(29):2187–96. CrossRef
Khan MK, Dangles O. A comprehensive review on flavanones, the major citrus polyphenols. J Food Compos Anal. 2014;33(1):85–104. CrossRef
El Gharras H. Polyphenols: food sources, properties and applications—a review. Int J Food Sci Technol. 2009;44(12):2512–8. CrossRef
Chun OK, Chung SJ, Song WO. Estimated dietary flavonoid intake and major food sources of US adults. J Nutr. 2007;137(5):1244–52. PubMed
Chen J, Mangelinckx S, Adams A, Wang Z, Li W, De Kimpe N. Natural flavonoids as potential herbal medication for the treatment of diabetes mellitus and its complications. Nat Prod Commun. 2015;10(1):187–200. PubMed
Li C, Schluesener H. Health-promoting effects of the citrus flavanone hesperidin. Critical Rev Food Sci Nutr. 2014 (just-accepted).
Woo Y, Shin SY, Hyun J, Lee SD, Lee YH, Lim Y. Flavanones inhibit the clonogenicity of HCT116 cololectal cancer cells. Int J Mol Med. 2012;29(3):403–8. PubMed
Pfeffer U, Ferrari N, Morini M, Benelli R, Noonan D, Albini A. Antiangiogenic activity of chemopreventive drugs. Int J Biol Markers. 2002;18(1):70–4. CrossRef
Nijveldt RJ, Van Nood E, Van Hoorn DE, Boelens PG, Van Norren K, Van Leeuwen PA. Flavonoids: a review of probable mechanisms of action and potential applications. Am J Clin Nutr. 2001;74(4):418–25. PubMed
Byrd JC, Peterson BL, Gabrilove J, Odenike OM, Grever MR, Rai K, Larson RA, Cancer BLG. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. Clin Cancer Res. 2005;11(11):4176–81. CrossRefPubMed
Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R. Randomized multicenter phase 2 study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7 + 3) in newly diagnosed acute myeloid leukemia. haematologica. 2015:haematol. 2015.125849.
NCI-60 screening methodology. https://dtp.cancer.gov/discovery_development/nci-60/methodology.htm. Accessed 2 Sept 2016.
Chazotte B. Labeling nuclear DNA using DAPI. Cold Spring Harbor Protoc. 2011;2011(1):pdb-prot5556.
Wagner K-D, Wagner N, Wellmann S, Schley G, Bondke A, Theres H, Scholz H. Oxygen-regulated expression of the Wilms’ tumor suppressor Wt1 involves hypoxia-inducible factor-1 (HIF-1). FASEB J. 2003;17(10):1364–6. PubMed
- HLBT-100: a highly potent anti-cancer flavanone from Tillandsia recurvata (L.) L.
Henry I. C. Lowe
Ngeh J. Toyang
Charah T. Watson
Kenneth N. Ayeah
- BioMed Central
Neu im Fachgebiet Onkologie
Mail Icon II